Treatment advances in relapsed/refractory large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive subtype of non-Hodgkin’s lymphoma. Despite a high success rate associated with first-line immunochemotherapy, approximately 40% of patients relapse or demonstrate resistance to treatment, significantly reducing life expectancy.¹